Taspoglutide is a glucagon-like peptide-1 agonist was studied in phase III clinical trials for the treatment patients with type 2 diabetes. However, in September 2010 Roche halted Phase III clinical trials due to gastrointestinal intolerability and serious hypersensitivity reactions experienced by some trial participants.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. | 2019-09 |
|
| Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide. | 2017-04 |
|
| Subcutaneous Bioavailability of Taspoglutide at 3 Different Injection Sites in Healthy Overweight/Obese Subjects. | 2015-11-01 |
|
| Utilization of model-based meta-analysis to delineate the net efficacy of taspoglutide from the response of placebo in clinical trials. | 2015-07 |
|
| Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. | 2015-05 |
|
| Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. | 2009-07 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00909597
taspoglutide 10mg sc weekly
Route of Administration:
Other
| Substance Class |
Protein
Created
by
admin
on
Edited
Wed Apr 02 19:53:02 GMT 2025
by
admin
on
Wed Apr 02 19:53:02 GMT 2025
|
| Protein Type | PEPTIDE |
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
2PHK27IP3B
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C98085
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB32528
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
56842233
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
C152518
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
m10479
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | Merck Index | ||
|
C541736
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
2PHK27IP3B
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
8975
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
275371-94-3
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
TASPOGLUTIDE
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
DB14027
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107860
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
100000124402
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY | |||
|
WW-10
Created by
admin on Wed Apr 02 19:53:02 GMT 2025 , Edited by admin on Wed Apr 02 19:53:02 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO_ACID_SUBSTITUTION | [1_2] [1_29] | SITE_SPECIFIC | .ALPHA.-AMINOISOBUTYRIC ACID | 1E7ZW41IQU | ||
| AMINO_ACID_SUBSTITUTION | [1_30] | SITE_SPECIFIC | ARGININAMIDE, L- | 29626ZE0WY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|